VRNA vs. ARES
VRNA (Verona Pharma plc) and ARES (Ares Management Corporation) are both stocks. VRNA operates in Biotechnology (Healthcare), while ARES operates in Asset Management (Financial Services). At a 0.16 correlation, their price movements are largely independent.
Performance
VRNA vs. ARES - Performance Comparison
Loading charts...
Returns By Period
VRNA
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
ARES
- 1D
- -4.07%
- 1M
- -1.32%
- YTD
- -23.01%
- 6M
- -26.26%
- 1Y
- -23.41%
- 3Y*
- 13.92%
- 5Y*
- 18.72%
- 10Y*
- 29.90%
VRNA vs. ARES - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 130.21% | 133.60% | -23.92% | 288.84% | -4.00% | 21.74% | -40.41% | -18.71% | -12.07% |
ARES Ares Management Corporation | -23.01% | -5.72% | 52.68% | 79.52% | -12.75% | 77.75% | 37.37% | 110.13% | -5.54% | 8.28% |
Correlation
The correlation between VRNA and ARES is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017 | 0.16 |
The correlation between VRNA and ARES shifts across timeframes, from -0.04 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
VRNA:
-$0.69
ARES:
$2.83
VRNA:
57.97
ARES:
4.21
VRNA:
$167.65M
ARES:
$6.31B
VRNA:
$159.52M
ARES:
$4.46B
VRNA:
-$40.86M
ARES:
$2.42B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VRNA vs. ARES — Risk / Return Rank
VRNA
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
ARES
VRNA vs. ARES - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Ares Management Corporation (ARES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VRNA | ARES | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 0.93 | — |
| Calmar ratioReturn relative to maximum drawdown | — | -0.48 | — |
| Martin ratioReturn relative to average drawdown | — | -0.92 | — |
Loading charts...
Drawdowns
VRNA vs. ARES - Drawdown Comparison
Loading charts...
Drawdown Indicators
| VRNA | ARES | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -49.73% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -49.05% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -49.73% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -49.73% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -49.73% | — |
Current DrawdownCurrent decline from peak | — | -35.17% | — |
Average DrawdownAverage peak-to-trough decline | — | -11.36% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 25.42% | — |
Volatility
VRNA vs. ARES - Volatility Comparison
Loading charts...
Volatility by Period
| VRNA | ARES | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | — | 12.55% | — |
Volatility (6M)Calculated over the trailing 6-month period | — | 35.66% | — |
Volatility (1Y)Calculated over the trailing 1-year period | — | 41.79% | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | — | 37.52% | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | — | 36.74% | — |
Dividends
VRNA vs. ARES - Dividend Comparison
VRNA has not paid dividends to shareholders, while ARES's dividend yield for the trailing twelve months is around 5.49%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARES Ares Management Corporation | 5.49% | 3.29% | 2.10% | 2.59% | 3.57% | 2.31% | 3.40% | 3.59% | 7.50% | 5.65% | 4.32% | 6.81% |
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
VRNA vs. ARES - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and Ares Management Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. ARES - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.
ARES - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported a gross profit of 1.47B and revenue of 1.53B. Therefore, the gross margin over that period was 96.1%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.
ARES - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported an operating income of 364.95M and revenue of 1.53B, resulting in an operating margin of 23.8%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.
ARES - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ares Management Corporation reported a net income of 142.59M and revenue of 1.53B, resulting in a net margin of 9.3%.
Frequently Asked Questions
VRNA and ARES have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for VRNA and ARES
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer